NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the ...

SALES FORECAST: Novartis's sales are forecast at $12.78 billion, according to analysts' estimates compiled by Visible Alpha. This compares with $11.42 billion the year before. Shares rose 5.1% over ...

Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00.Invest ...

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...

Ameritas Advisory Services LLC lowered its position in shares of Novartis AG (NYSE:NVS – Free Report) by 2.7% during the 4th ...

Novartis AG (NOVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure ...